MOA

New IBD Mechanisms of Action Are Poised to Gain EU5 Patient Switches as Anti-TNF Therapy Efficacy Fades in Ulcerative Colitis and Crohn's Disease, According to Spherix Global Insights

Retrieved on: 
Tuesday, August 16, 2022
Molecule, Crohn's disease, Infliximab, Diagnosis, Failure, AbbVie, CD, MOA, Gastroenterology, BMS, Patient, NASA RealWorld-InWorld Engineering Design Challenge, TNF, Safety, JAK, Nephrology, Ustekinumab, Ulcerative colitis, Janssen, Adalimumab, Upadacitinib, Time, Kwaku Amoa-Awuah, EMA, Pharmaceutical industry, Medical imaging, Generic drug, IBD, Ozanimod, Filgotinib, UC, EU

EXTON, Pa., Aug. 16, 2022 /PRNewswire/ -- According to the latest report published as part of Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (EU) service, EU gastroenterologists (n=285) have accelerated their switching of ulcerative colitis (UC) and Crohn's disease (CD) patients from anti-TNF therapies to treatments that include new pathways such as IL12/IL23 inhibition, α4β7 integrin binding, JAK inhibition, and S1P modulation.The Spherix study includes 1,280 unique IBD patient records from the EU5 (France, Germany, Italy, Spain, and the UK) that encapsulate patient-level data.

Key Points: 
  • The report also identifies a significant level of opportunity that still exists for new pathways and agents in IBD.
  • More specifically, 27% of UC patients and 30% of CD patients who have recently switched did so because of secondary efficacy failure.
  • The biosimilar therapies (infliximab and adalimumab) are the two treatment options most likely to trigger an efficacy-based switch.
  • In fact, when combining biosimilars and brands, TNF therapy represents the switch-from agent for a majority of all UC and CD patients.

Global Burns Market Report to 2032 - Insight, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022
Health, Pharmaceutical, Third-degree atrioventricular block, United Kingdom, Population, Female, Burn, Incidence, MOA, Research, Patient, Epidemiology, Review, ROA, Male, Report, SWOT, CAGR, Second degree, III, Medical device, Dietary supplement, Pharmaceutical industry

The "Burns - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Burns - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • The Burns market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Burns market size from 2022 to 2032.
  • The Report also covers current Burns treatment practice, market drivers, market barriers, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
  • A detailed review of the Burns market; historical and forecasted is included in the report, covering the 7MM drug outreach.

ZIVO Reports that USDA Claims Regulatory Jurisdiction for New Coccidiosis Treatment

Retrieved on: 
Wednesday, August 10, 2022
Health, Infectious Diseases, Agriculture, Natural Resources, Pharmaceutical, Biotechnology, Veterinary, Coccidiosis, Digestion, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Poultry, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Face, Drug resistance, Growth, Securities Exchange Act of 1934, Center for Veterinary Medicine, Disease, MOA, Security (finance), Research, Parasitic disease, Bird, Letter, USDA, Center, Licensure, CVB, NASDAQ, Veterinary biologic, Securities Act of 1933, Chicken, Veterinary medicine, Health, Vaccine

The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that face growing anticoccidial drug resistance.

Key Points: 
  • The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that face growing anticoccidial drug resistance.
  • Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.
  • Im delighted with todays announcement that demonstrates ZIVOs commitment to advancing our product candidate toward commercialization and provides regulatory clarity.
  • With regulatory jurisdiction now confirmed, we will advance discussions with the CVB on the final product development plan, regulatory strategy and data requirements for licensure.

ONEIL Joint Venture Named to $7.4 Billion FAA eFAST Contract

Retrieved on: 
Thursday, August 4, 2022
SBA, CEO, Technology, MOA, LLC, Mentorship, Department, Compliance, Engineering, Small business, Contract, Acquisition, Department of Defense Architecture Framework, Program, Partnership, FAA, Solution, LinkedIn, Time, Publishing, Focused assessment with sonography for trauma, Airline, Management, HUBZone

MIAMISBURG, Ohio, Aug. 4, 2022 /PRNewswire-PRWeb/ -- O'Neil & Associates, (ONEIL) in partnership with EIDOS Technologies, LLC, today announced that their joint venture company, ONEIDOS, was awarded a seat on a $7.4 billion contract. The official prime award notice means aviation customers can quickly and easily work with ONEIDOS through the Electronic Federal Aviation Administration (FAA) Accelerated and Simplified Tasks (eFAST), Master Order Agreement (MOA) as an 8(a), HUBZone, and Small Business.

Key Points: 
  • Prime Award Secures Customer Efficiencies, Opportunities
    MIAMISBURG, Ohio, Aug. 4, 2022 /PRNewswire-PRWeb/ -- O'Neil & Associates , (ONEIL) in partnership with EIDOS Technologies, LLC , today announced that their joint venture company, ONEIDOS, was awarded a seat on a $7.4 billion contract.
  • eFAST supports firm-fixed price, cost reimbursable, time and materials, labor hour and other contract types as appropriate.
  • Through eFAST, customers can reduce the time it takes to hire a contractor by as much as 65 percent.
  • Since Fiscal Year 2010, the eFAST program has awarded more than $4.4 billion in contracts to small businesses.

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 4, 2022
Goal, Melanoma, Securities Exchange Act of 1934, NASDAQ, Bristol Myers Squibb, Herpes simplex virus, PFS, Breast cancer, CD40L, Marketing, RP3, CRC, RP1, Protein, RP2, Safety, FDA, Cancer, Antigen, Immunogenic cell death, NSCLC, GLOBE, U.S. Securities and Exchange Commission, Colorectal cancer, Sale, Coronavirus, Large-cell lung carcinoma, MOA, Neck, GI, SCCHN, RPX, Neoplasm, Lung cancer, Head, HCC, CSCC, Patient, Review, Hepatocellular carcinoma, ORR, Uveal melanoma, Clinical trial, Securities Act of 1933, Drug Quality and Security Act, Skin, Security (finance), D, CR, MSI, Lymph, Company, Progression-free survival, Program, Tumor microenvironment, Investment, Forward-looking statement, Research, Toxicity, TME, Squamous cell carcinoma, Pharmaceutical industry, Medical imaging, Vaccine, Nivolumab, Sanofi, Regeneron Pharmaceuticals

WOBURN, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2022 and provided a business update.

Key Points: 
  • Our ambition to establish a major skin cancer franchise, built off of our lead RP1 program, is progressing to plan.
  • R&D Expenses: Research and development expenses were$29.5 millionfor the first quarter ended June 30, 2022, as compared to$18.6 millionfor the first quarter ended June 30, 2021.
  • S,G&A Expenses: Selling, general and administrative expenses were$11.4 millionfor the first quarter endedJune 30, 2022, as compared to$8.8 millionfor the first quarter endedJune 30, 2021.
  • Our actual results could differ materially from the results described in or implied by such forward-looking statements.

Museum of Illusions® to Open New Museum in America's Biggest Mall

Retrieved on: 
Wednesday, August 3, 2022
Universe, People, Travel, Mall of America, The Lego Group, MOA, Museum, Multimedia, SEA, Creativity, City, B&B Theatres, CEO, Sea, Nickelodeon Universe, View, Tourism, Illusion, Mall

ATLANTA, Aug. 3, 2022 /PRNewswire/ -- Museum of Illusions®, a global leader in "edutainment" and the biggest chain of private museums worldwide, announced today the global brand's plan to open a new location in one of the most-visited malls in the United States. The brand new Museum of Illusions is set to open in Mall of America ("MOA") in Minneapolis, Minnesota in early 2023.

Key Points: 
  • The brand new Museum of Illusions is set to open in Mall of America ("MOA") in Minneapolis, Minnesota in early 2023.
  • Visitors to the new museum can expect a truly unforgettable experience, as the Minneapolis Museum of Illusions will be joining many entertainment attractions in this mall, home to more than 520 stores.
  • "Museum of Illusions is excited to bring its unique, interactive and immersive experience to one of the largest entertainment spaces in the world," said Jonathan Benjamin, CEO of Museum of Illusions.
  • For more information about the Museum of Illusions and its franchise opportunities, visit www.museumofillusions.com or email at [email protected] .

Replimune to Present at Two Upcoming Investor Conferences

Retrieved on: 
Monday, August 1, 2022
MOA, NASDAQ, TME, RPX, Immunogenic cell death, Neoplasm, GLOBE, Antigen, Safety, Tumor microenvironment, Pharmaceutical industry, Vaccine

Replimunes proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.

Key Points: 
  • Replimunes proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.
  • The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response.
  • This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options.
  • For more information, please visit www.replimune.com .

Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus

Retrieved on: 
Monday, August 1, 2022
Vaccine, Severe acute respiratory syndrome coronavirus 2, Pulmonary fibrosis, GLOBE, Galectin, Degenerative disease, Protein, Human, Outline, Journal, COVID-19, Carbohydrate, Fibrosis, Autophagy, MOA, Nature, Cancer, Virology, Outline of health sciences, Cell, Glycoconjugate, Clinical trial, Inflammation, Viral load, Patient, Coronavirus, Mode of action, Stroke, Lists of World Heritage Sites, Control, Article, Variants of SARS-CoV-2, Canadian International Council, Hypoxia, Pharmaceutical industry, Lectin

BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral causing diseases announced today that the journal of International Journal of Health Sciences1 released a peer-reviewed article, “Carbohydrate ProLectin-M, a Galectin-3 Antagonist, Blocks SARS-CoV-2 Activity”, that supports ProLectin-M’s in vitro Mode of Action and the initial clinical data results reported in a previous article, referred to below. ProLectin-M is the Company’s leading drug molecule in its pipeline to treat viral infections.

Key Points: 
  • ProLectin-M is the Companys leading drug molecule in its pipeline to treat viral infections.
  • The journal article begins to outline and further define the mechanism of action (MOA) behind the oral galectin inhibitor Prolectin-M.
  • The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases and bind to the conserved region of the spike protein commonly known as the galectin fold.
  • ProLectin-M is an orally administered experimental new drug candidate that targets the Carbohydrate Binding Domain portion on the SARS-CoV-2, coronavirus.

The Dugger Law Firm, PLLC: Former MOA Special Counsel & Deputy Director of Vetting Martha Perez-Pedemonti Files Discrimination & Retaliation Class Action Against NYC

Retrieved on: 
Wednesday, July 27, 2022
Civic, Appointment, Commissioner, FMLA, Confidentiality, New York City Department of Citywide Administrative Services Police, Female, Sexual harassment, Culture, City, MS, New York City Human Rights Law, MOA, Defendant, Landmark, Family and Medical Leave Act of 1993, New York City Law Department, Principal, Law, New York City Public Advocate, Policy, Family, Color, DCAS, Complaint, EEO, New York City Landmarks Preservation Commission, Insurance, Property management, Health insurance, Agency

NEW YORK, July 26, 2022 /PRNewswire-PRWeb/ -- Former Mayor's Office of Appointments ("MOA") Special Counsel and Deputy Director of Vetting Martha Perez-Pedemonti has filed an individual and class action complaint against the City of New York ("NYC"), former Director and Principal EEO Officer for MOA Joni Kletter ("Kletter"), NYC Law Department EEO Officer Sosimo Fabian ("Fabian"), and NYC Agency Counsel Michael Levario ("Levario").

Key Points: 
  • The complaint further alleges FMLA retaliation and interference claims against Defendants NYC and Kletter.
  • In addition to individual claims, Ms. Perez-Pedemonti alleges class claims, for injunctive and declaratory relief, on behalf of all NYC employees who filed EEO complaints against a Commissioner, Head of Agency, and/or EEO Officer.
  • The complaint alleges that these, and other EEO policies, resulted in a disparate impact on the class through disproportionate rates of discipline, resignation, and/or termination.
  • It further alleges that NYC had a policy or practice of retaliation against employees who made sex discrimination, race discrimination, and/or related retaliation EEO complaints against Commissioners, Agency Heads, and/or EEO Officers.

Aviceda Therapeutics Announces Key Opinion Leader in Ophthalmology Drug Development Tarek S. Hassan, MD to Join Management Team as Chief Development Officer

Retrieved on: 
Monday, July 25, 2022
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Hospitals, Science, Clinical Trials, Executive Committee, American Academy, University, Board of directors, Foundation, ASRS, CEO, American Academy of Ophthalmology, Geographic atrophy, AMD, RWC, Board, Therapy, DRS, MOA, Consultant, Inflammation, Clinical trial, Journal, Partnership, Aviceda, The Washington Campus Board of Directors, Senior, Oakland University, Patient, GA, AAO, Book, S-1 Executive Committee, Society, Editing, Management, Pharmaceutical industry, Fine chemical, Ophthalmology, Retina, MD

Mohamed Genead, David Callanan, Michael Tolentino, Derek Kunimoto, and Christopher Scott, as part of the executive management team.

Key Points: 
  • Mohamed Genead, David Callanan, Michael Tolentino, Derek Kunimoto, and Christopher Scott, as part of the executive management team.
  • Aviceda is honored to have one of the most renowned and successful leaders in retina and strategic drug development join the Aviceda team in this key position.
  • With our lead product about to enter clinical trials for GA associated with dry AMD, this is an ideal time for Tarek to join our management team.
  • I am honored to join the outstanding team of thought leaders in the fields of retina, glycobiology, and immune therapy at Aviceda, said Dr. Tarek Hassan.